Research, page-2030

There are so many catalysts ahead with all that's being worked through behind the scenes, that it does not seem wise to be selling. We know that there is volatility in our stock prices so that any positive news should re-rate it significantly.

We've made more important progress as a company with milestones and recognition of technology by the wider community since earlier this year. With noticeable traction on the clinical side at an opportune time including multiple studies due for publication in the near term as well presentations at importance global conferences, work on the commercial side to expand ANZ, and maturing commercial discussions in the USA (we've got a sales force in the USA and Australia that are motivated to achieve results including a few new hires in the last yr), reimbursement process now more advanced and anticipated FDA applications / approvals in FY24 (including for our breakthrough CT:VQ product) among a vast array of things they have and haven't mentioned. I've also noticed people from new organisations (including USA academic orgs) showing love for our tech, these are positive signs.

Patience is our friend, like AF is practicing with his substantial holding, having not sold a share and he would feel the paper wealth impact more than all of us. You can tell this is a company here for the long term, putting in all the works to build a sustainable business into the future, helped by the supportive team culture at 4DMedical (calling out the charity run on the weekend to support Cystic Fibrosis Australia).